Petter Quist-Paulsen1. 1. Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. petter.quist-paulsen@stolav.no
Abstract
PURPOSE OF REVIEW: Randomized trials have suggested that the beneficial effects of statins could extend to mechanisms beyond cholesterol reduction. Investigations have shown that statins are associated with reduced plasma markers of inflammation, reduced T-cell and monocyte activation, and reduced blood clotting. These effects could be explained by the inhibition of L-mevalonic acid synthesis, thus affecting cell-signalling pathways. However, it has been difficult to evaluate whether the nonlipid effects of statins translate into clinically meaningful outcomes. RECENT FINDINGS: Inflammation, as measured by C-reactive protein (CRP), has been established as an independent cardiovascular risk factor, even in persons with low-density lipoprotein (LDL)-cholesterol. Statins have anti-inflammatory effects, and lower CRP. Reducing both LDL-cholesterol and CRP is important in order to decrease the risk of cardiovascular events. Statins significantly reduce the risk of venous thrombosis. It is probable that this effect goes beyond lipid lowering. The clinical benefit of statin therapy in infectious diseases remains to be determined by randomized controlled trials. SUMMARY: Statins have anti-inflammatory properties that are clinically important in lowering cardiovascular risk. It is probable, but not definitely proven, that some of the benefits of statins are due to their nonlipid effects.
PURPOSE OF REVIEW: Randomized trials have suggested that the beneficial effects of statins could extend to mechanisms beyond cholesterol reduction. Investigations have shown that statins are associated with reduced plasma markers of inflammation, reduced T-cell and monocyte activation, and reduced blood clotting. These effects could be explained by the inhibition of L-mevalonic acid synthesis, thus affecting cell-signalling pathways. However, it has been difficult to evaluate whether the nonlipid effects of statins translate into clinically meaningful outcomes. RECENT FINDINGS:Inflammation, as measured by C-reactive protein (CRP), has been established as an independent cardiovascular risk factor, even in persons with low-density lipoprotein (LDL)-cholesterol. Statins have anti-inflammatory effects, and lower CRP. Reducing both LDL-cholesterol and CRP is important in order to decrease the risk of cardiovascular events. Statins significantly reduce the risk of venous thrombosis. It is probable that this effect goes beyond lipid lowering. The clinical benefit of statin therapy in infectious diseases remains to be determined by randomized controlled trials. SUMMARY: Statins have anti-inflammatory properties that are clinically important in lowering cardiovascular risk. It is probable, but not definitely proven, that some of the benefits of statins are due to their nonlipid effects.
Authors: Jean Schmidt; Tanaz A Kermani; Francesco Muratore; Cynthia S Crowson; Eric L Matteson; Kenneth J Warrington Journal: J Rheumatol Date: 2013-04-01 Impact factor: 4.666
Authors: Nathan Vandjelovic; Hong Zhu; Hara P Misra; Ryan P Zimmerman; Zhenquan Jia; Yunbo Li Journal: Mol Cell Biochem Date: 2011-12-30 Impact factor: 3.396
Authors: Nuntakorn Thongtang; Margaret R Diffenderfer; Esther M M Ooi; Bela F Asztalos; Gregory G Dolnikowski; Stefania Lamon-Fava; Ernst J Schaefer Journal: Metabolism Date: 2012-09-25 Impact factor: 8.694
Authors: Nuntakorn Thongtang; Margaret R Diffenderfer; Esther M M Ooi; Bela F Asztalos; Gregory G Dolnikowski; Stefania Lamon-Fava; Ernst J Schaefer Journal: Atherosclerosis Date: 2012-11-23 Impact factor: 5.162
Authors: J L Ebersole; R J Kryscio; C Campbell; D F Kinane; J McDevitt; N Christodoulides; P N Floriano; C S Miller Journal: J Periodontal Res Date: 2016-08-23 Impact factor: 4.419